India to United States: Actinomycin Export Trade Route
India has recorded 13 verified shipments of Actinomycin exported to United States, representing a combined trade value of $1.8M USD. This corridor is served by 7 active Indian exporters, with an average shipment value of $138.9K USD. The leading Indian exporter is EUGIA PHARMA SPECIALITIES LIMITED, which accounts for 100% of total export value with 5 shipments worth $1.8M USD. On the buying side, EUGIA US LLC is the largest importer in United States with $1.0M USD in purchases. The top 3 suppliers — EUGIA PHARMA SPECIALITIES LIMITED, MYGENIC HEALTHCARE PRIVATE LIMITED, KOIT BIOPHARMA PRIVATE LIMITED — together control of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to United States Actinomycin corridor is one of India's established pharmaceutical export routes, with 13 shipments documented worth a combined $1.8M USD. The route is dominated by EUGIA PHARMA SPECIALITIES LIMITED, which alone accounts for roughly 100% of all export value, reflecting the consolidated nature of India's actinomycin manufacturing sector.
Across 7 active suppliers, the average shipment value stands at $138.9K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 82% of all shipments, consistent with actinomycin's non-urgent bulk-order profile.
Shipment activity peaks during UNAVAILABLE, with an average transit time of 33 days port-to-port. The route has recorded an annual growth rate of 14%, placing it at rank #34 among India's top actinomycin export destinations globally.
On the import side, key buyers of Indian actinomycin in United States include EUGIA US LLC, EUGIA US LLC,, LUIS MENDEZ and 6 others. EUGIA US LLC is the single largest importer with 3 shipments valued at $1.0M USD.
